Xalkori

The U.S. Food and Drug Administration (FDA) has approved Xalkori (crizotinib) to treat patients with late-stage non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase (ALK)…

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Poll